Details of the Drug Combination

General Information of Drug Combination (ID: DCFG1WJ)

Drug Combination Name
PF-04634817 Salicylhydroxamic acid
Indication
Disease Entry Status REF
Macular Edema, Diabetic Phase 2 [1]
Component Drugs PF-04634817   DM0GBB5 Salicylhydroxamic acid   DMGLSPC
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of PF-04634817
Disease Entry ICD 11 Status REF
Diabetic nephropathy GB61.Z Phase 2 [2]
Indication(s) of Salicylhydroxamic acid
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
Salicylhydroxamic acid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) TT3PQ2Y PYRD_PLAF7 Inhibitor [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01994291) A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
2 ClinicalTrials.gov (NCT01712061) A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy. U.S. National Institutes of Health.
3 Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.